Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nathalie Gaspar, Michela Casanova, Francisco José Bautista Sirvent, Rajkumar Venkatramani, Bruce Morland, Marion Gambart, Estelle Thebaud, Sandra J Strauss, Franco Locatelli, Soledad Gallego Melcon, Adela Canete, Stefan S. Bielack, Claudia Rossig, Isabelle Aerts, Perrine Marec-Berard, Silvija Kraljevic, Seiichi Hayato, Cixin He, Corina E. Dutcus, Quentin Campbell-Hewson
Institutions: Institut Gustave Roussy, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Infantil Universitario Niño Jesús, Texas Children's Hospital, Birmingham Children's Hospital, Centre Hospitalier Universitaire de Toulouse, Hôpital des Enfants, Centre Hospitalier Universitaire de Nantes, Hôpital Mère-Enfant, University College London, University of Pavia, Bambino Gesù Children's Hospital, Vall d'Hebron Hospital Universitari, Hospital Universitari i Politècnic La Fe, Olgahospital, Klinikum Stuttgart, University of Münster, University Hospital Münster, Université Paris Sciences et Lettres, Institut Curie, Centre Léon Bérard, Eisai (United Kingdom), Eisai (Japan), Eisai (United States), Royal Victoria Infirmary, Great North Children's Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889673034
